First-in-human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations.
Mark S FinemanChristine L N BryantKevin ColbertThomas H JozefiakJohn S PetersenMichael HorowitzJiten VoraChristopher K RaynerPaul WabnitzAshish NimgaonkarPublished in: Diabetes, obesity & metabolism (2023)
GLY-200 is safe and generally well tolerated at doses of ≤2.0 g twice daily. Pharmacodynamic results mimic the biomarker signature observed after Roux-en-Y gastric bypass and duodenal exclusion devices, indicating a pharmacological effect in the proximal small intestine. This study represents the first clinical demonstration that duodenal exclusion can be achieved with an oral drug and supports further development of GLY-200 for the treatment of obesity and/or T2D.